Business Wire

IWBI Crosses Major Global Milestones in Advancing Health and Well-Being

1.2.2021 17:00:00 EET | Business Wire | Press release

Share

The International WELL Building Institute (IWBI), the global authority on how we can use our buildings and communities to advance the health and well-being of the people inside, announced today that WELL projects have now crossed the 1.5 billion square foot mark across more than 80 countries. The milestone is evidence of accelerating global adoption and tremendous growth from less than a year ago, when WELL projects surpassed 500 million square feet in nearly 60 countries.

In June 2020, IWBI launched the WELL Health-Safety Rating, leveraging its existing expertise and feedback from the 600-member IWBI Taskforce on COVID-19. Drawing on a subset of features from the WELL Building Standard (WELL), the WELL Health-Safety Rating is an evidence-based, third-party verified rating for all new and existing buildings and space types that is focused on operational policies, maintenance protocols, emergency plans and stakeholder engagement strategies to help organizations prioritize the health and safety of their staff, visitors and stakeholders, and get back to business during these pandemic times.

More than 8,500 facilities have enrolled in the WELL Health-Safety Rating to date, including iconic buildings like Yankee Stadium and the Empire State Building, global financial service organizations like JPMorgan Chase, hotel leaders like Aimbridge Hospitality, telecommunications organizations like T-Mobile, real estate developers like Brookfield Properties and Kilroy Realty, fitness organizations like Life Time, and many others.

“The pandemic quickly shifted the conversation on health, and IWBI’s role in helping mitigate the impact of the virus and supporting people’s safety and well-being is now more clear than ever,” said Paul Scialla, Founder of IWBI and CEO of its parent company, Delos.

“The pace of adoption has been remarkable, with registrations across WELL offerings now averaging 2 million square feet every day,” said Rachel Hodgdon, IWBI President and CEO. “This is thanks to our dedicated community from around the world - our WELL APs, WELL Faculty, members, customers and advisors.”

WELL APs and WELL Faculty are an active and growing community that brings education about WELL to colleagues and clients around the world. Over 16,000 individuals have registered for or achieved the WELL AP credential and have helped IWBI quickly respond to rising demand.

“These are enormous accomplishments in the six years since WELL first launched,” continued Hodgdon. “While the pandemic has disrupted so much of our lives, it’s also presented us with the opportunity to grow a movement that has the potential to do so much good. Each of these milestones is an affirmation of the need for people first places, and we can’t wait to share what we have in store.”

About the International WELL Building Institute

The International WELL Building Institute (IWBI) is a public benefit corporation and the world’s leading organization focused on deploying people first places to advance a global culture of health. IWBI mobilizes its community through the administration of the WELL Building Standard (WELL) and the WELL Health-Safety Rating, management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellbeing everywhere. More information on WELL can be found here.

International WELL Building Institute pbc is a wholly owned subsidiary of Delos. International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL Portfolio, WELL Portfolio Score, The WELL Conference, We Are WELL, the WELL Community Standard, WELL Health-Safety Rating, WELL Health-Safety Rated, WELL Health-Equity, WELL and others, and their related logos are trademarks or certification marks of International WELL Building Institute in the United States and other countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jamie Matos
media@wellcertified.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives European Union Approval for Restylane ® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810880899/en/ The lower face plays a pivotal role in overall facial balance, influencing proportions and profile.2 This region is an increasing area of concern for patients, with around one in four people expressing concerns related to lower face sagging and chin shape.5 When asked about their facial priorities, a third of people pointed out issues with their chin shape – a key contributor to facial definition and structural harmony.5 Genetic factors and age-related changes can lead to reduced chin d

Stonebranch is Again Named a Leader in the 2026 Gartner ® Magic Quadrant ™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 18:00:00 EEST | Press release

Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build, manage, and optimize automation at enterprise scale.” Stonebranch UAC helps organizations unify, manage, and scale automation ac

Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 17:09:00 EEST | Press release

Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboration, and help deliver mission-ready capabilities faster. “Bringing Frontgrade’s capabilities to Huntsville is a meaningful milestone for me, both personally and professionally. For decades, this

Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 16:00:00 EEST | Press release

Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized authority on applied AI, she is a Gartner-recognized thought leader and author on AI SaaS and product en

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical collaboration will explore potential targeted combination approaches for patients with RAS-addicted cancers Potential drug combinations for development as part of the clinical collaboration will include certain BeOne assets and Revolution Medicines’ four clinical RAS(ON) inhibitors: daraxonrasib, a RAS(ON) multi-selective inhibitor; zo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye